Thursday, September 18, 2025 9/18/2025

Novel therapy to prevent alveolar bone loss in severe periodontitis

Award Number: R43DE033577
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2024
PERIOD OF PERFORMANCE END DATE: 08/14/2026

Group Awards By:

View Award Description

Novel therapy to prevent alveolar bone loss in severe periodontitis - Novel therapy to prevent alveolar bone loss in severe periodontitis Abstract Periodontal disease affects almost half of US adults 30 years and older. More advanced disease, periodontitis, leads to retraction of the gums from the teeth, with loss of alveolar bone, and ultimately loss of teeth. A key step in progression of periodontitis involves the loss of alveolar bone that provides the underlying support for the tooth. This process is mediated by bone-degrading osteoclasts (OC). Osteoclast activation by inflammatory mediators disrupts bone homeostasis, leading to loss of bone mass. OC differentiation from OC progenitor cells (OCP) is modulated by a cascade of integrated signaling culminating in stimulation by RANKL that ultimately leads to fusion of OCP to form the active, multinucleated OC. While multiple fusogens, including the dendritic cell-specific transmembrane protein (DC-STAMP) and CD9, are recognized, recent data suggest a pivotal role for OC-stimulatory transmembrane protein (OC-STAMP). OC-STAMP knock-out mice exhibit diminished alveolar bone loss in a standard ligature-induced model of periodontitis. Unlike anti-DC-STAMP, anti- OC-STAMP down-regulates expression of CD9. These studies of osteoclastogenesis involving OC-STAMP suggest a potential therapeutic intervention for periodontitis using an anti-OC-STAMP monoclonal antibody. Proof-of-concept work utilized a murine-specific anti-OC-STAMP murine monoclonal antibody. During this Phase 1 project, we will identify and evaluate a panel of human anti-human OC-STAMP monoclonal antibodies. A lead antibody will be identified using a ligature-induced periodontitis model in a human OC-STAMP knock-in mouse model. This work will produce a novel therapeutic to slow or even potentially halt loss of alveolar bone and teeth in severe periodontitis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	PANORAMA RESEARCH INCORPORATED	1230 BORDEAUX DR	SUNNYVALE	CA	94089	SANTA CLARA	USA	Oral Diseases and Disorders Research	001	1	8/26/2025	NEW	$0
2025	2024	PANORAMA RESEARCH INCORPORATED	1230 BORDEAUX DR	SUNNYVALE	CA	94089	SANTA CLARA	USA	Oral Diseases and Disorders Research	000	1	10/17/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $304,019 )
2024	2024	PANORAMA RESEARCH INCORPORATED	1230 BORDEAUX DR	SUNNYVALE	CA	94089	SANTA CLARA	USA	Oral Diseases and Disorders Research	000	1	8/14/2024	NEW	$304,019
														Subtotal = $304,019

Grand Total All Awards = $304,019

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel therapy to prevent alveolar bone loss in severe periodontitis

Award Number: R43DE033577

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2024

PERIOD OF PERFORMANCE END DATE: 08/14/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer